AACR 2025 Poster 5497

Trodelvy Screening in a Large Organoid Panel Reveals the Importance of Functional Assays for Predicting Tumor Response

Marten Hornsveld, Jinxi Wang, Jun Zhou, Xiaolong Tu, Ling Chen, Huajun Zhou, Wendy Lam, Cinthya Del Angel Zuvirie, Peter van Schaik, Mariusz Madej, Hester Bange, Lenno Krenning, Jessie J.J. Wang, Ludovic Bourre, Marrit Putker

Antibody-drug conjugates (ADCs) are a cutting-edge approach in targeted cancer therapy, combining the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapeutic agents. In vitro efficacy testing is a critical step in ADC development and requires models that exhibit physiological human target-protein expression, growth factor signalling and DNA damage responses to allow for accurate predictions of efficacy.

Tumor organoids, 3D cell cultures derived from patient tumors, closely mimic the pathology, genetic and expression profiles and drug responses of their tumors of origin and therefore are robust preclinical models for ADC testing. Here, we present an organoid-based ADC testing platform, that combines the strength of patient-derived organoids with our advanced 3D high content imaging platform

Download this Poster to Discover:

• How organoid panel screening captures a wide-range of responses to Sacituzumab-Govitecan/SN38
  
  
• How High Content Imaging (HCI) can be leveraged to get deep insights into ADCs MoA and internalization
  
  
• How functional screenings are a key tool to determine efficacy when drug sensitivity does not correlate with mRNA or protein expression

Download the Poster Now!